Targets of emerging therapies for viral hepatitis B and C
| Autor: | Daniel Yerly, Florian Bihl, Andreas Cerny, Loriana Di Giammarino |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Pharmacology
Hepatitis B virus Nucleoside analogue viruses Hepatitis C virus Genetic enhancement Clinical Biochemistry Viral hepatitis b Biology Hepatitis B medicine.disease_cause Antiviral Agents Hepatitis C Virology Virus Substrate Specificity Immune therapy Drug Discovery Immunology medicine Humans Molecular Medicine Protease inhibitor (pharmacology) medicine.drug |
| Zdroj: | Expert Opinion on Therapeutic Targets. 10:833-850 |
| ISSN: | 1744-7631 1472-8222 |
| DOI: | 10.1517/14728222.10.6.833 |
| Popis: | Viral hepatitis B and C, structurally two completely different viruses, commonly infect human hepatocytes and cause similar clinical manifestations. Since their discovery, IFN has been a pillar in the treatment. However, because of the different natures of the viruses, therapeutic approaches diverge and new treatment targets are tailored specifically for each virus. Herein, the authors analyse therapeutic approaches for hepatitis B virus (HBV) and hepatitis C virus (HCV) and focus on emerging concepts that are under clinical evaluation. In particular, promising viral inhibitors for HBV and HCV are reviewed and the current status of research for gene therapy for HCV is described. Immune therapy is a fast-moving field with fascinating results which include therapeutic vaccines and toll-like receptor agonists that could improve tomorrow's treatment approaches. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|